Artios expands leadership team as alnodesertib moves toward late-stage development

Artios Pharma Limited announced the appointment of six senior leaders to strengthen its late-stage development capabilities and accelerate its potential first-in-class oncology pipeline. The appointments come as the company rapidly advances alnodesertib into late-stage development and potential U.S. commercialization, executes a randomized Phase 2 study for ART6043, and advances its DNA Damage Response antibody drug conjugate platform toward clinical development.

On February 16, 2026, the company said Roy W. Ware, PhD, MBA joined as Chief Manufacturing and Technology Officer, leading Chemistry, Manufacturing and Supply Chain operations for the DDR-based therapeutics pipeline. Caryn Barnett was appointed Vice President of Clinical Operations, and Pablo Lee, MD, MBA was appointed Vice President of Medical Affairs. The company said these leadership appointments collectively establish an integrated, late-stage drug development capability that aligns manufacturing, clinical execution, and global medical affairs as alnodesertib advances into late-stage development and potential commercialization in the U.S. while the company simultaneously executes a Phase 2 study for ART6043.

On May 4, 2026, Artios announced that Jeremy B. Fitch, MBA joined as Chief Business Officer and will shape corporate business development and strategic partnerships. Michael A. Alrutz, J.D., Ph.D. joined as General Counsel and will oversee legal, corporate governance, regulatory compliance, risk management, and intellectual property management, while serving as a strategic partner to the Board of Directors and executive leadership team. Guy C. Ruble, PharmD was appointed Vice President of Regulatory Affairs to lead the company’s regulatory strategy and initiatives.

The company said the May appointments came at a pivotal inflection point as it progresses alnodesertib toward potential registration and commercialization. Artios said it has three potentially first-in-class DDR programs under rapid development.

According to the company, Ware most recently served as Chief Manufacturing and Technology Officer at Chimerix, where he led Chemistry, Manufacturing and Controls and Supply Chain operations and oversaw submissions that supported FDA approvals for Tembexa for smallpox and Modeyso for H3 K27M-mutant diffuse midline glioma. Barnett previously held senior clinical operations leadership roles at Eli Lilly, Endocyte, and Chimerix, where she led clinical operations through registration trials, FDA submissions and FDA inspections. Lee previously led U.S. and global medical affairs organizations at companies including Chimerix and Verastem Oncology, including launch planning and execution of Modeyso in H3 K27M-mutant diffuse midline glioma.

Artios said Fitch spent the past 15 years in Lilly’s Corporate Business Development group, most recently as Vice President of Transactions, and led strategic deal-making spanning M&A, asset acquisitions and divestitures, and licensing agreements. The company said Alrutz most recently was SVP, General Counsel, Secretary, and Chief Compliance Officer at Chimerix, where he led SEC compliance, board governance, intellectual property management, and legal aspects of corporate transactions, including the company’s $935 million all-cash merger with Jazz Pharmaceuticals as the company prepared for commercialization of Modeyso. Ruble most recently served as Vice President of Regulatory Affairs at Iovance Biotherapeutics, where he led the U.S. FDA accelerated approval of AMTAGVI.